Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

Although lung cancer survival is improving in the United States, 21% of patients with lung cancer did not receive treatment ...

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...

The family of a retired Westchester school employee is reaching out to the community for help as they raise funds for a ...

Identifying lung cancer at its earliest stage before symptoms develop allows for earlier treatment and the potential for cure ...

IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation ...

2024 — Researchers have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to target non-responsive ... A New Ventilator-on-a-Chip Model to ...